Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.22 USD | -0.84% | +2.82% | +32.90% |
May. 21 | Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing | MT |
May. 20 | Immunome Completes Purchase of Antibodies From Atreca | MT |
Financials (USD)
Sales 2024 * | 10.04M | Sales 2025 * | 844K | Capitalization | 852M |
---|---|---|---|---|---|
Net income 2024 * | -193M | Net income 2025 * | -170M | EV / Sales 2024 * | 84.9 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1,010 x |
P/E ratio 2024 * |
-4
x | P/E ratio 2025 * |
-5.24
x | Employees | 55 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.92% |
1 day | -0.84% | ||
1 week | +2.82% | ||
Current month | +1.14% | ||
1 month | +3.57% | ||
3 months | -42.71% | ||
6 months | +77.75% | ||
Current year | +32.90% |
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-10-18 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | Jan. 01 |
Director/Board Member | 70 | Nov. 06 | |
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 14.22 | -0.84% | 1,069,390 |
24-05-23 | 14.34 | -0.55% | 767,701 |
24-05-22 | 14.42 | +5.64% | 1,170,209 |
24-05-21 | 13.65 | -1.09% | 604,460 |
24-05-20 | 13.8 | -0.22% | 1,342,376 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.90% | 852M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- IMNM Stock